Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
CERT 
Certara Inc (CERT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: CERT (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Analysis of Past Performance
Type Stock | Historic Profit -2.68% | Avg. Invested days 35 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.59B USD | Price to earnings Ratio - | 1Y Target Price 14.44 |
Price to earnings Ratio - | 1Y Target Price 14.44 | ||
Volume (30-day avg) 1385776 | Beta 1.6 | 52 Weeks Range 9.41 - 19.18 | Updated Date 04/2/2025 |
52 Weeks Range 9.41 - 19.18 | Updated Date 04/2/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.08 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -3.13% | Operating Margin (TTM) 14.4% |
Management Effectiveness
Return on Assets (TTM) 0.75% | Return on Equity (TTM) -1.15% |
Valuation
Trailing PE - | Forward PE 21.74 | Enterprise Value 1725179794 | Price to Sales(TTM) 4.13 |
Enterprise Value 1725179794 | Price to Sales(TTM) 4.13 | ||
Enterprise Value to Revenue 4.48 | Enterprise Value to EBITDA 23.84 | Shares Outstanding 161018000 | Shares Floating 120930790 |
Shares Outstanding 161018000 | Shares Floating 120930790 | ||
Percent Insiders 2.27 | Percent Institutions 96.56 |
Analyst Ratings
Rating 3.73 | Target Price 14.28 | Buy - | Strong Buy 4 |
Buy - | Strong Buy 4 | ||
Hold 7 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Certara Inc
Company Overview
History and Background
Certara, Inc. was founded in 2008 through the merger of Tripos International and Pharsight Corporation. It has grown through acquisitions and organic development to become a leading provider of biosimulation software and services.
Core Business Areas
- Software: Develops and markets biosimulation software, including modeling and simulation (M&S) platforms.
- Services: Offers biosimulation consulting services, including model development, data analysis, and regulatory support.
Leadership and Structure
The leadership team consists of experienced professionals in the pharmaceutical and technology industries. The company has a functional organizational structure with dedicated teams for software development, sales, marketing, and services.
Top Products and Market Share
Key Offerings
- Simcyp PBPK: Simcyp is a physiologically-based pharmacokinetic (PBPK) modeling and simulation platform used to predict drug absorption, distribution, metabolism, and excretion (ADME) in humans and animals. It has an estimated 30% market share. Competitors include Open Systems Pharmacology (Free). Revenue estimated to be $80 million.
- Phoenix NLME: Phoenix NLME is a pharmacokinetic (PK) and pharmacodynamic (PD) modeling and simulation platform used to analyze clinical trial data. Market Share is approximately 35%. Competitors include NONMEM. Revenue estimated to be $60 million.
Market Dynamics
Industry Overview
The biosimulation market is growing due to increasing complexity in drug development, regulatory requirements for model-informed drug development (MIDD), and demand for personalized medicine.
Positioning
Certara is a leader in the biosimulation market, with a strong portfolio of software and services. Its competitive advantages include its established reputation, scientific expertise, and integrated platform.
Total Addressable Market (TAM)
The global biosimulation market is expected to reach $5.3 billion by 2029. Certara is well-positioned to capture a significant share of this growing market.
Upturn SWOT Analysis
Strengths
- Leading market position
- Comprehensive product portfolio
- Strong scientific expertise
- Established customer base
Weaknesses
- Reliance on pharmaceutical industry
- High switching costs for customers
- Limited diversification
Opportunities
- Expansion into new therapeutic areas
- Growth in emerging markets
- Adoption of AI/ML in biosimulation
- Increasing regulatory focus on MIDD
Threats
- Competition from open-source software
- Economic downturn impacting R&D spending
- Changing regulatory landscape
- Data security and privacy concerns
Competitors and Market Share
Key Competitors
- DIS
- ACAD
- WCG
Competitive Landscape
Certara has a strong competitive position in the biosimulation market due to its comprehensive product portfolio, scientific expertise, and established customer base. However, it faces competition from open-source software and larger companies with broader product offerings.
Major Acquisitions
BaseCase
- Year: 2018
- Acquisition Price (USD millions): 88.2
- Strategic Rationale: Expanded Certara's strategic capabilities in market access and pricing.
Growth Trajectory and Initiatives
Historical Growth: Certara has experienced strong growth in recent years, driven by increasing adoption of biosimulation in drug development.
Future Projections: Analysts expect Certara to continue to grow in the coming years, driven by increasing demand for its software and services.
Recent Initiatives: Recent strategic initiatives include expanding its product portfolio, entering new markets, and investing in AI/ML capabilities.
Summary
Certara is a strong company in the biosimulation market with a leading position and comprehensive offerings. Its growth is driven by increased adoption of biosimulation in drug development. However, it faces competition and is reliant on the pharmaceutical industry, so it needs to look out for evolving regulatory landscape and market dynamics, including open-source alternatives.
Similar Companies
ACAD
ACADIA Pharmaceuticals Inc
ACAD
ACADIA Pharmaceuticals Inc
DIS
Walt Disney Company
DIS
Walt Disney Company
Sources and Disclaimers
Data Sources:
- Company Filings
- Industry Reports
- Analyst Estimates
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Market share data is estimated and may vary. Financial data should be independently verified.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Certara Inc
Exchange NASDAQ | Headquaters Radnor, PA, United States | ||
IPO Launch date 2020-12-11 | CEO & Director Dr. William F. Feehery Ph.D. | ||
Sector Healthcare | Industry Health Information Services | Full time employees 1487 | Website https://www.certara.com |
Full time employees 1487 | Website https://www.certara.com | ||
Certara, Inc., together with its subsidiaries, provides technology-enabled services and software products for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solutions to predict pharmacokinetics and pharmacodynamics; Simcyp simulator, a mechanistic biosimulation platform for physiologically based pharmacokinetic simulation; Simcyp Discovery for scientists working on pre-investigational new drug and translational stages; Simcyp Biopharmaceutics for formulation scientists; and Simcyp Secondary Intelligence that integrates toxicology with quantitative analysis of large networks of molecular and functional biological changes. The company also provides Phoenix WinNonlin, a platform for non-compartmental analysis; Phoenix Hosted, which offers a secured and validated Certara Amazon Web Services workspace; Phoenix NLME, a population modeling and simulation software; and Pirana Modeling Workbench, which provides modelers with a structure to facilitate the iterative processes. In addition, it offers Chemaxon JChem engines, a chemical search engine; Chemaxon Compound Registration, which supports a streamlined lead optimization process workflow; Chemaxon Design Hub, a design and tracking platform for drug discovery teams and their external collaborators; Certara D360 software, a scientific informatics system for small molecule and biologics discovery research; and Chemaxon Marvin, a chemical drawing tool. Further, the company provides pinnacle 21, a cloud-based platform for clinical data automation, standardization, and validation; Pinnacle 21 Data Exchange to define data standards and specifications; Metadata Repository that enables study design using controlled and standardized data; CoAuthor software, which creates and assembles regulatory submissions and medical publications; and GlobalSubmit, a submissions management software. Certara I
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.